Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Shen, Man; Zhang, Jiajia; Tang, Ran; Yuhao, Wang; Zhan, Xiaokai; Fan, Sibin; Huang, Zhongxia; Zhong, Yuanyuan; Li, Xin

doi:10.1002/cam4.4313

Cited by 8 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, a recent meta-analysis indirectly compared lenalidomide vs. ixazomib maintenance treatment, showing a lack of benefit from ixazomib maintenance as compared with lenalidomide both in TE and NTE patients ( 72 ). Two ixazomib-based RW studies focused on front-line therapy ( 68 ) and maintenance therapy ( 69 ) in NTE patients are reported in Table 4 .…”

Section: Proteasome Inhibitorsmentioning

confidence: 99%

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

2022

View full text Add to dashboard Cite

The current strategies for the treatment of multiple myeloma (MM) have improved, thanks to effective drug classes and combination therapies, for both the upfront and relapsed settings. Clinical trials for newly diagnosed transplant-ineligible patients led to the approval of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) in combination with anti-CD38 monoclonal antibodies (mAbs), to be administered during the induction phase before transplantation and during maintenance treatment, with lenalidomide recommended until relapse. In relapsed/refractory patients, the complex treatment scenario currently includes several options, such as triplets with anti-CD38 mAbs plus IMiDs or PIs, and novel targeted molecules. Comparisons among clinical trials and real-world data showed a good degree of reproducibility of some important results, particularly in terms of overall response rate, progression-free survival, and overall survival. This may help clinicians towards a proper selection of the best treatment options, particularly in real-world settings. However, as compared with the management of real-world settings, clinical trials have some pitfalls in terms of outcome and especially in terms of safety and quality of life. In fact, trials include younger and presumably healthier patients, excluding those with worst clinical conditions due to MM features (e.g., renal insufficiency or bone disease, which can impair the performance status) and comorbidities (e.g., cardiac and pulmonary disease), thus resulting in a possible lack of representativeness of data about the patients enrolled. In this review, we analyze comparable and discrepant results from clinical trials vs. real-world settings published in the last 10 years, focusing on different drugs and combinations for the treatment of MM and providing an overview of treatment choices.

show abstract

Section: Proteasome Inhibitorsmentioning

confidence: 99%

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

2022

View full text Add to dashboard Cite

show abstract

“…33 Clinical test demonstrated that the adverse events' incidence of bortezomib-associated regimes were higher than those of ixazomib-related regimes in the therapy of relapsed/refractory MM, especially peripheral sensory neuropathy. 36 Our current study indicated that among 21 patients in IRd group, 28.56% of patients occurred adverse reaction including 2 of grade 1-2 leukopenia, 2 of grade 1-2 hemocytopenia, 1 of grade 1-2 diarrhea and 1 of grade 3-4 diarrhea, respectively. Whereas, among 31 patients in VRd group, 51.61% of patients suffered from adverse reaction containing 2 of leukopenia, 5 of hemocytopenia, 6 of peripheral sensory neuropathy, and 3 of limb numbness.…”

Section: Discussionmentioning

confidence: 48%

“…Nevertheless, research suggested that the drug‐related adverse reactions of IRd were mostly within the tolerable range 33 . Clinical test demonstrated that the adverse events’ incidence of bortezomib‐associated regimes were higher than those of ixazomib‐related regimes in the therapy of relapsed/refractory MM, especially peripheral sensory neuropathy 36 . Our current study indicated that among 21 patients in IRd group, 28.56% of patients occurred adverse reaction including 2 of grade 1–2 leukopenia, 2 of grade 1–2 hemocytopenia, 1 of grade 1–2 diarrhea and 1 of grade 3–4 diarrhea, respectively.…”

Section: Discussionmentioning

confidence: 99%

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone

et al. 2022

View full text Add to dashboard Cite

Background To compare the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatment in newly diagnosed multiple myeloma (MM). Methods This was a single‐center retrospective analysis in Xiangtan Central Hospital. A total of 52 newly diagnosed MM patients from June 2019 to June 2021 were enrolled and divided into the IRd ( n = 21) and VRd ( n = 31) groups. After 4 cycles of chemotherapy, the best response and adverse events were recorded. Moreover, the progression‐free survival (PFS) and overall survival (OS) were calculated. Results Patients in IRd group and VRd group showed similar PFS (Log‐rank p = 0.70), OS (Log‐rank p = 0.61) and overall response rate (83.87% vs 90.48%, p = 0.803). In addition, patients in VRd group showed lower Eastern Cooperative Oncology Group scores ( p = 0.047), and higher incidence of peripheral sensory neuropathy (0.00% vs 19.35%, p = 0.032) than that of patients in IRd group. Conclusion Compared to VRd regimen, IRd had the similar efficacy, better safety, and may be more convenient for patients with poor basic condition for newly diagnosed MM. This study provides an insight for physicians to use IRd as first‐line treatment in MM.

show abstract

“…As a result, two antichlamydial agent candidates-namely, N-(2-pyrazinecarbonyl)-D-phenylalanine-L-leucine boronic anhydride (BTZ) and (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3methylbutylboronic acid (MLN9708, IXA)-have been identified. BTZ and IXA are wellknown proteasome inhibitors and approved anticancer drugs for treating multiple myeloma and mantle cell lymphoma [13][14][15]. First, whether both compounds affect chlamydial growth was examined.…”

Section: Both Btz and Ixa But Not Delanzomib Strictly Suppress The Ch...mentioning

confidence: 99%

Bortezomib Eliminates Persistent Chlamydia trachomatis Infection through Rapid and Specific Host Cell Apoptosis

Itoh

Kurihara

Yoshimura

et al. 2022

IJMS

View full text Add to dashboard Cite

Chlamydia trachomatis, a parasitic intracellular bacterium, is a major human pathogen that causes millions of trachoma, sexually transmitted infections, and pneumonia cases worldwide. Previously, peptidomimetic inhibitors consisting of a hydrophobic dipeptide derivative exhibited significant inhibitory effects against chlamydial growth. Based on this finding, this study showed that both bortezomib (BTZ) and ixazomib (IXA), anticancer drugs characterized by proteasome inhibitors, have intensive inhibitory activity against Chlamydia. Both BTZ and IXA consisted of hydrophobic dipeptide derivatives and strongly restricted the growth of Chlamydia (BTZ, IC50 = 24 nM). In contrast, no growth inhibitory effect was observed for other nonintracellular parasitic bacteria, such as Escherichia coli. BTZ and IXA appeared to inhibit chlamydial growth bacteriostatically via electron microscopy. Surprisingly, Chlamydia-infected cells that induced a persistent infection state were selectively eliminated by BTZ treatment, whereas uninfected cells survived. These results strongly suggested the potential of boron compounds based on hydrophobic dipeptides for treating chlamydial infections, including persistent infections, which may be useful for future therapeutic use in chlamydial infectious diseases.

show abstract

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 8 publications

References 24 publications

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone

Bortezomib Eliminates Persistent Chlamydia trachomatis Infection through Rapid and Specific Host Cell Apoptosis

Contact Info

Product

Resources

About